Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
hVIVO plc (HVO.L)
London, GB
hVIVO plc (HVO) operates as a premier full-service Contract Research Organisation (CRO) focused on early-phase clinical development, globally recognized as the leader in human challenge trials. The company provides a complete spectrum of clinical development services to a wide-ranging and growing client base, which includes seven of the world's ten largest biopharmaceutical companies. A key specialisation for hVIVO is orchestrating human challenge trials across numerous infectious and respiratory diseases, utilising its advanced, London-based quarantine facility, the largest of its kind globally. Additionally, the company offers extensive virology and immunology laboratory services through its hLAB division. Through its German subsidiary, CRS, hVIVO manages a 120-bed capacity across sites in Mannheim and Kiel, delivering early-phase clinical trial expertise, including first-in-human and proof-of-concept studies. Its other subsidiary, Venn Life Sciences, contributes to the biopharma sector by providing specialist early drug development consulting and biometry services. The Group collectively offers integrated drug development solutions, covering stages from preclinical research up to Phase II trials, supported by patient recruitment via FluCamp. Moreover, its five clinical sites facilitate outpatient Phase II and III trials, ensuring a streamlined and effective transition from drug discovery to late-stage development.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.47% | +2.47% | +10.67% | -2.35% | +46.64% | +31.75% | -4.60% | -46.45% | -78.66% | -69.26% | -76.29% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 6 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-25.4% Q4'25: -24.8% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-156.1% Q4'25: -148.9% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-37.6% Q4'25: -32.7% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-0.8% Q4'25: -26.3% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-0.9% ★ Q4'25: -61.4% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%-0.4% ★ Q4'25: -1.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×3.43× ★ Q4'25: -1.14× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 5 EPS Ana. |
Dec 2027 7 Rev. Ana. 5 EPS Ana. |
Dec 2028 4 Rev. Ana. 2 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
8.47M
est: 8.25M (+2.6%)
|
15.27M
est: 16.03M (-4.8%)
|
15.45M
est: 15.67M (-1.4%)
|
12.55M
est: 11.88M (+5.6%)
|
3.28M
est: 19.74M (-83.4%)
|
20.60M
est: 25.39M (-18.8%)
|
36.86M
est: 38.07M (-3.2%)
|
48.48M
est: 49.90M (-2.9%)
|
56.04M
est: 67.21M (-16.6%)
|
62.73M
est: 62.70M (+0.0%)
|
46.77M
est: 46.86M (-0.2%)
|
50.44M
48.78M – 51.08M
+7.6% YoY
|
54.95M
51.17M – 56.48M
+8.9% YoY
|
60.08M
59.88M – 60.27M
+9.3% YoY
|
68.01M
64.51M – 69.42M
+13.2% YoY
|
| EBITDA |
520.3K
est: 425.4K (+22.3%)
|
-77.6K
est: 826.1K (-109.4%)
|
-806.1K
est: 807.3K (-199.8%)
|
-3.67M
est: 612.3K (-699.1%)
|
-4.83M
est: 1.02M (-574.8%)
|
-8.55M
est: 1.31M (-753.9%)
|
3.07M
est: 1.96M (+56.4%)
|
2.70M
est: 2.57M (+4.9%)
|
14.02M
est: 10.28M (+36.3%)
|
17.80M
est: 9.59M (+85.6%)
|
4.31M
est: 7.17M (-39.9%)
|
7.72M
7.46M – 7.82M
+7.6% YoY
|
8.41M
7.83M – 8.64M
+8.9% YoY
|
9.19M
9.16M – 9.22M
+9.3% YoY
|
10.41M
9.87M – 10.62M
+13.2% YoY
|
| EBIT |
177.9K
est: -127.4K (+239.6%)
|
-778.2K
est: -247.4K (-214.6%)
|
-1.60M
est: -241.8K (-560.6%)
|
-4.51M
est: -183.4K (-2,360.2%)
|
-5.46M
est: -304.6K (-1,691.2%)
|
-10.61M
est: -391.8K (-2,607.1%)
|
504.0K
est: -587.5K (+185.8%)
|
-232.0K
est: -770.1K (+69.9%)
|
11.30M
est: 5.78M (+95.5%)
|
14.24M
est: 5.39M (+164.1%)
|
-349.0K
est: 4.03M (-108.7%)
|
4.34M
4.20M – 4.39M
+7.6% YoY
|
4.73M
4.40M – 4.86M
+8.9% YoY
|
5.17M
5.15M – 5.18M
+9.3% YoY
|
5.85M
5.55M – 5.97M
+13.2% YoY
|
| Net Income |
11.1K
est: 3.18M (-99.7%)
|
453.5K
est: 14.27M (-96.8%)
|
-1.37M
est: -19.85M (+93.1%)
|
-4.30M
est: -806.6K (-433.6%)
|
-5.59M
est: -9.96M (+43.9%)
|
-10.79M
est: -6.55M (-64.8%)
|
-74.0K
est: -184.5K (+59.9%)
|
-776.0K
est: 5.18M (-115.0%)
|
16.12M
est: 17.45M (-7.6%)
|
10.65M
est: 10.89M (-2.2%)
|
-5.99M
est: -2.72M (-120.7%)
|
-3.49M
-5.46M – -2.05M
-28.6% YoY
|
-1.14M
-4.01M – 651.6K
+67.2% YoY
|
3.17M
666.4K – 3.38M
+377.3% YoY
|
10.01M
9.34M – 10.28M
+215.6% YoY
|
| SGA |
8.81M
est: 3.88M (+127.0%)
|
16.03M
est: 7.53M (+112.8%)
|
15.77M
est: 7.36M (+114.2%)
|
3.81M
est: 5.58M (-31.8%)
|
1.96M
est: 9.28M (-78.9%)
|
10.96M
est: 11.93M (-8.1%)
|
17.86M
est: 17.89M (-0.2%)
|
23.54M
est: 23.45M (+0.4%)
|
24.17M
est: 24.44M (-1.1%)
|
26.13M
est: 22.80M (+14.6%)
|
—
est: 17.04M (-100.0%)
|
18.34M
17.74M – 18.57M
+7.6% YoY
|
19.98M
18.61M – 20.54M
+8.9% YoY
|
21.84M
21.77M – 21.91M
+9.3% YoY
|
24.73M
23.45M – 25.24M
+13.2% YoY
|
| EPS |
0.00
est: 0.00 (-93.5%)
|
0.01
est: 0.02 (-60.9%)
|
-0.02
est: -0.03 (+21.6%)
|
-0.06
est: 0.00 (-4,985.3%)
|
-0.03
est: -0.01 (-134.2%)
|
-0.02
est: -0.01 (-89.2%)
|
0.00
est: 0.00 (+62.7%)
|
0.00
est: 0.01 (-115.8%)
|
0.02
est: 0.03 (-7.2%)
|
0.02
est: 0.02 (-3.1%)
|
-0.01
est: 0.00 (-99.3%)
|
-0.01
-0.01 – 0.00
-16.3% YoY
|
0.00
-0.01 – 0.00
+68.4% YoY
|
0.00
0.00 – 0.00
+283.6% YoY
|
0.01
0.01 – 0.01
+395.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-26 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-19 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-18 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-15 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-14 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yamin Mohammed Khan | Chief Executive Officer & Director | 697.0K | — |
| Stephen Pinkerton | Chief Financial Officer & Executive Director | 349.0K | male |
| Andrew Catchpole | Chief Scientific Officer | — | male |
| Teja Marathe-Sarvadikar | Head of Quality Assurance | — | female |
| Thomas Forst | Chief Medical Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HVO.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
